NCM Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

NCM Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.08M	Buy	18,722 +6	+0%	+$345	0.33%	74
2026 Q1	$1.14M	Sell	18,716 -993	-5%	-$57.9K	0.41%	65
2025 Q4	$1.06M	Sell	19,709 -1,525	-7%	-$73.4K	0.39%	69
2025 Q3	$958K	Buy	21,234 +8	+0%	+$374	0.37%	71
2025 Q2	$983K	Sell	21,226 -100	-0.5%	-$4.91K	0.4%	62
2025 Q1	$1.3M	Sell	21,326 -300	-1%	-$17.5K	0.58%	42
2024 Q4	$1.22M	Buy	21,626 +238	+1%	+$13.3K	0.55%	44
2024 Q3	$1.11M	Sell	21,388 -200	-0.9%	-$9.38K	0.53%	45
2024 Q2	$897K	Buy	21,588 +6,700	+45%	+$300K	0.47%	50
2024 Q1	$807K	Sell	14,888 -1,034	-6%	-$52.7K	0.45%	58
2023 Q4	$817K	Buy	15,922 +700	+5%	+$36.7K	0.5%	58
2023 Q3	$883K	Sell	15,222 -85	-0.6%	-$5.21K	0.63%	44
2023 Q2	$979K	Hold	15,307	–	–	0.68%	42
2023 Q1	$1.06M	Hold	15,307	–	–	0.79%	33
2022 Q4	$1.1M	Hold	15,307	–	–	0.73%	37
2022 Q3	$1.09M	Sell	15,307 -200	-1%	-$14.5K	0.82%	34
2022 Q2	$1.19M	Hold	15,507	–	–	0.84%	40
2022 Q1	$1.13M	Sell	15,507 -500	-3%	-$33.6K	0.71%	40
2021 Q4	$998K	Buy	+16,007	New	+$939K	0.89%	32

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

NCM Capital Management's BMY Position: Q2 2026 in Review

NCM Capital Management increased its Bristol-Myers Squibb (BMY) stake by 0.03% in Q2 2026, buying an estimated $345 and bringing the position to 18,722 shares worth $1.08M. The position accounts for 0.33% of the portfolio, ranked #74.

NCM Capital Management first reported a position in BMY in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.3M in Q1 2025. 2,523 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

NCM Capital Management held 18,722 shares of Bristol-Myers Squibb worth $1.08M as of Q2 2026.
NCM Capital Management bought 6 Bristol-Myers Squibb shares in Q2 2026, an estimated $345.
Bristol-Myers Squibb made up 0.33% of NCM Capital Management's portfolio in Q2 2026, its #74 holding.
NCM Capital Management first reported a position in Bristol-Myers Squibb in Q4 2021 and has held it in 19 quarters since.
NCM Capital Management's Bristol-Myers Squibb position peaked at $1.3M in Q1 2025.
2,523 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on NCM Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.